Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Kiyoshi Okazuka, MD, Nobuhiro Tsukada, Kota Sato, MD, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, MD, Tadao Ishida, MD, Kenshi Suzuki

Blood (2017) 130 (Supplement 1): 4542.

https://doi.org/10.1182/blood.V130.Suppl_1.4542.4542

Published: 2017

Journal Articles

Feasibility of a Cell-Based Oncolytic Virotherapy Targeting Bone Marrow Lesions of Multiple Myeloma

Kota Sato, MD, Muneyoshi Futami, MD PhD, Ung Weng Chit, Takafumi Nakamura, MD PhD, Arinobu Tojo, MD PhD

Blood (2016) 128 (22): 4499.

https://doi.org/10.1182/blood.V128.22.4499.4499

Published: 2016

Journal Articles

Thymidine Kinase-Deleted, let7a-Regulated Vaccinia Virus Specifically Infects and Lyses Myeloma Cells in a Mouse Myeloma Model

Muneyoshi Futami, MDPhD, Kota Sato, MD, Takafumi Nakamura, PhD, Arinobu Tojo, MD PhD

Blood (2014) 124 (21): 2082.

https://doi.org/10.1182/blood.V124.21.2082.2082

Published: 2014

NARROW

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Feasibility of a Cell-Based Oncolytic Virotherapy Targeting Bone Marrow Lesions of Multiple Myeloma

Thymidine Kinase-Deleted, let7a-Regulated Vaccinia Virus Specifically Infects and Lyses Myeloma Cells in a Mouse Myeloma Model

Email alerts

ASH Publications

American Society of Hematology

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Feasibility of a Cell-Based Oncolytic Virotherapy Targeting Bone Marrow Lesions of Multiple Myeloma

Thymidine Kinase-Deleted, let7a-Regulated Vaccinia Virus Specifically Infects and Lyses Myeloma Cells in a Mouse Myeloma Model

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only